The Hershey Company reported a surge in sales for its mint and gum products during the first quarter of 2026 [1, 2].
This trend highlights how the widespread adoption of GLP-1 weight-loss medications is creating unexpected ripple effects across consumer markets. As more people use these drugs, companies are identifying new demand patterns based on the medications' side effects.
The company specifically noted that sales of its Ice Breakers line increased by eight percent [1, 2]. Executives said this growth is due to the side effects associated with GLP-1 medications, such as Ozempic, which can cause dry mouth and bad breath.
"We've seen a clear uptick in demand for our Ice Breakers as consumers look for relief from dry mouth caused by GLP-1 medications," CEO Michele Buck said.
The growth in these categories serves as a hedge for the company as it navigates a changing health landscape. A Hershey spokesperson said that people on Ozempic often complain about bad breath, and the company's mints are helping them feel fresher.
This shift in consumer behavior is not isolated to a single product line. The company's CFO said the rise in GLP-1 usage is directly translating into higher sales for the gum and mint categories [3].
The reporting comes from the company's headquarters in Hershey, Pennsylvania, reflecting a broad trend across the U.S. market. While these medications are primarily used for weight loss and diabetes, the resulting "Ozempic breath" has created a specific niche for oral care products.
“Ice Breakers sales increased by 8% in the first quarter [1, 2].”
The correlation between GLP-1 drug usage and increased mint sales suggests that pharmaceutical trends can drive short-term revenue gains in unrelated consumer goods sectors. As these medications become more prevalent, food and beverage companies may pivot their product strategies to address the specific physiological side effects of long-term drug use.
